The Board of Directors of Magle Group has today, pursuant to the authorization from the Annual General Meeting on 25 April 2024, resolved to carry out the Consideration Issue. Those entitled to receive shares in the Consideration Issue are shareholders who are registered in Amniotics' share register on the record date for the Merger on 1 October 2024. The reason for the deviation from the shareholders' preferential rights is that the newly issued shares shall constitute the merger consideration in the Merger. Following the Consideration Issue, Magle Group will have a total of 11,201,917 outstanding shares and votes. Furthermore, the Consideration Issue entails that Magle Group's share capital increases by SEK 20,095.85 to a total of SEK 560,095.85. For existing shareholders in Magle Group, who do not receive shares in the Consideration Issue, the dilution amounts to a total of approximately 3.6 percent of the number of shares and votes (calculated on the total number of shares and votes in Magle Group after the Consideration Issue).

The shareholders who are registered in Amniotics’ share register, as of the record date on 1 October 2024, will receive merger consideration. For six thousand eight hundred (6,800) shares in Amniotics, one (1) share in Magle Group will be received. Delivery of shares in Magle Group, i.e. the merger consideration, is intended to commence on or about 8 October 2024. Trading in Magle Group's shares will take place as usual and will not be affected by the merger process.

Advisors
Vator Securities AB is financial advisor in connection with the Merger. Advokatfirman Schjødt is legal advisor to Magle Group in connection with the Merger.

For enquiries, please contact:

Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21

For administrative questions regarding the Merger, please contact your bank or the nominee registered as holder of your shares.

About Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com.

Vator Securities is Magle Group's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Important information
In the information below, "this press release" refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction's securities law. Decisions regarding the Merger shall be made solely on the basis of information stated in the merger document relating to the Merger, and to independent analyses of the information therein. You should read the merger document, which is available on Magle Group’s and Amniotics’ webpages: www.maglegroup.com and www.amniotics.com, to obtain more complete information on the Merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision.